Kobo Biotech
BSE: KOBO · Commodity Chemicals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Kobo Biotech's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Kobo Biotech Limited is an Indian company specialising in the manufacturing and distribution of bulk drugs, active pharmaceutical ingredients, and biotechnology products. The firm focuses on chemical synthesis and post-harvest technologies to enhance yields in the pharmaceutical and agricultural sectors.
Business Model
The company generates revenue through the research, development, and large-scale processing of essential chemical compounds and biochemicals. It operates as a niche manufacturer serving both domestic and international markets.
Growth Outlook
Growth is expected to be driven by the company's strategic focus on specialised chemical synthesis and the expansion of its biotechnology product portfolio. Continued investment in research and development remains central to its market positioning.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight regarding the manufacturing of active pharmaceutical ingredients and chemical compounds.
- Market Volatility. As a small-cap entity, the company is susceptible to fluctuations in commodity chemical prices and broader economic instability.
- Operational Risks. The reliance on complex chemical synthesis processes exposes the firm to potential supply chain disruptions and manufacturing inefficiencies.
Start your research today
Unlock AI insights, financials, peers and live data on Kobo Biotech and 5,000+ companies — free.
Peers · Commodity Chemicals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Kobo BiotechKOBO | ₹13 Cr | — | — | — | — | — | — | +138.7% |
Blue Pearl Agriventures LimitedBPAGRI | ₹525 Cr | — | — | — | 2.7% | — | — | -92.2% |
Primo ChemicalsPRIMO | ₹517 Cr | 32.82 | 7.31 | -2.7% | 15.8% | 4.0% | 7.1% | -16.6% |
POCL EnterprisesPOEL | ₹460 Cr | 10.53 | 7.57 | — | 5.3% | 21.3% | 33.7% | -37.2% |
Mangalam OrganicMANORG | ₹437 Cr | 21.41 | 8.88 | 17.3% | 13.6% | 6.8% | 15.9% | -7.2% |
Lords Chloro Alkali LimitedLORDSCHLO | ₹402 Cr | 11.52 | 7.91 | 29.8% | 17.3% | 15.6% | 14.1% | -18.7% |
As of Mar 2025
Financials
Kobo Biotech
BSE: KOBO · Commodity Chemicals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Kobo Biotech's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Kobo Biotech Limited is an Indian company specialising in the manufacturing and distribution of bulk drugs, active pharmaceutical ingredients, and biotechnology products. The firm focuses on chemical synthesis and post-harvest technologies to enhance yields in the pharmaceutical and agricultural sectors.
Business Model
The company generates revenue through the research, development, and large-scale processing of essential chemical compounds and biochemicals. It operates as a niche manufacturer serving both domestic and international markets.
Growth Outlook
Growth is expected to be driven by the company's strategic focus on specialised chemical synthesis and the expansion of its biotechnology product portfolio. Continued investment in research and development remains central to its market positioning.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight regarding the manufacturing of active pharmaceutical ingredients and chemical compounds.
- Market Volatility. As a small-cap entity, the company is susceptible to fluctuations in commodity chemical prices and broader economic instability.
- Operational Risks. The reliance on complex chemical synthesis processes exposes the firm to potential supply chain disruptions and manufacturing inefficiencies.
Start your research today
Unlock AI insights, financials, peers and live data on Kobo Biotech and 5,000+ companies — free.
Peers · Commodity Chemicals
As of Mar 2025